A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-Possible stimulated reporting?

Vaccine

Volumn 30, Issue 14, 2012, Pages 2421-2426

  McNeil, Michael M ^a   Arana, Jorge ^a   Stewart, Brock ^a   Hartshorn, Mary ^b   Hrncir, David ^b   Wang, Henry ^d   Lamias, Mark ^a,c   Locke, Michael ^a,c   Stamper, John ^a   Tokars, Jerome I ^a   Engler, Renata J ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Military Vaccine Agency   (United States)

^c SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Adult vaccination; H1N1 vaccine safety; VAERS

Indexed keywords

DIPHENHYDRAMINE; IBUPROFEN; INFLUENZA VACCINE; INFUSION FLUID; LORAZEPAM; PARACETAMOL;

2009 H1N1 INFLUENZA; ADULT; ARTHRALGIA; ARTICLE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEALTH SURVEY; HUMAN; INFLUENZA VACCINATION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYALGIA; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT ATTITUDE; PRIORITY JOURNAL; RACE DIFFERENCE; RHINORRHEA; SEX DIFFERENCE; SOLDIER; WEAKNESS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MILITARY FACILITIES; MILITARY PERSONNEL; SEX FACTORS; YOUNG ADULT;

EID: 84862807397     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.072     Document Type: Article

References (27)

1. Varricchio F., Iskander J., DeStefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23:287-294.
2. R Development Core Team R: a language and environment for statistical computing 2010, R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0, http://www.R-project.org.
3. Gidudu J., Kohl K.S., Halperin S., Hammer S.J., Heath P.T., Hennig R., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008, 26:6800-6813.
4. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110:105-123.
5. Safranek T.J., Lawrence D.N., Kurland L.T., Culver D.H., Wiederholt W.C., Hayner N.S., et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991, 133:940-951.
6. Baggs J., Gee J., Lewis E., Fowler G., Benson P., Lieu T., et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011, 127(Suppl. 1):S45-S53.
7. Salmon D.A., Akhtar A., Mergler M.J., Vannice K.S., Izurieta H., Ball R., et al. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 2011, 127(Suppl. 1):S78-S86.
8. Federal Immunization Safety Task Force. Federal Plans to Monitor Immunization Safety for the Pandemic 2009 H1N1 Influenza Vaccination Program. Accessed 6 June 2011 at: http://www.flu.gov/professional/federal/monitor_immunization_safety.html.
9. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28:7248-7255.
10. Assistant Secretary for Defense (Reserve Affairs) Memorandum: Department of Defense Pandemic Vaccine Guidance for 2009 H1N1 Pandemic. Washington, DC; 2009.
11. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States 1991-2001. Morb Mortal Wkly Rep 2003, 52:1-24.
12. McMahon A.W., Zinderman C., Ball R., Gupta G., Braun M.M. Comparison of military and civilian reporting rates for smallpox vaccine adverse events. Pharmacoepidemiol Drug Saf 2007, 16:597-604.
13. US General Accounting Office Defense Health Care: DoD needs to improve force health protection and surveillance processes 2003.
14. Porter C.K., Bowens M.J., Tribble D.R., Putnam S.D., Sanders J.W., Riddle M.S. Attitudes towards vaccines and infectious disease risk among US troops. Hum Vaccines 2008, 4:298-304.
15. Riddle M.S., Patel S.S., Sanders J.W., Armstrong A.W., Putnam S.D., Schlett C.D., et al. Attitudes toward predeployment and experimental vaccinations among troops deployed to operation Iraqi Freedom and Operation Enduring Freedom. J Travel Med 2008, 15:68-76.
16. Porter C.K., Tribble D.R., Halvorson H., Putnam S.D., Sanders J.W., Riddle M.S. Cross-sectional survey of anthrax vaccine coverage and KAP among deployed US military. Hum Vaccines 2009, 5:765-769.
17. Pica-Branco D., Hudak R.P. US military service members' perceptions of Anthrax Vaccine Immunization Program. Mil Med 2008, 173:429-433.
18. Polak S., Riddle M.S., Tribble D.R., Armstrong A.W., Mostafa M., Porter C.K. Pre-deployment vaccinations and perception of risk among US military personnel. Hum Vaccines 2011, 7:762-767.
19. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
20. Cook I.F. Sex differences in injection site reactions with human vaccines. Hum Vaccines 2009, 5:441-449.
21. Beyer W.E., Palache A.M., Kerstens R., Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996, 15:65-70.
22. Pittman P.R. Aluminum-containing vaccine associated adverse events: role of route of administration and gender. Vaccine 2002, 20:S48-S50.
23. Klein S.L., Jedicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10:338-349.
24. Kharabsheh S., Al-Otoum H., Clements J., Abbas A., Khuri-Bulos N., Belbesi A., et al. Mass psychogenic illness following tetanus-diphtheria toxoid vaccination in Jordan. Bull World Health Organ 2001, 79:764-770.
25. Clements C.J. Mass psychogenic illness after vaccination. Drug Saf 2003, 26:599-604.
26. Huang W.T., Hsu C.C., Lee P.I., Chuang J.H. Mass psychogenic illness in nationwide in-school vaccination for pandemic influenza A (H1N1) 2009, Taiwan, November 2009-January 2010. Euro Surveill 2010, 15:1-3.
27. Miller E.R., Haber P., Hibbs B., Broder K. Surveillance for adverse events following immunization using the Vaccine Adverse Event Reporting System (VAERS). Manual for the Surveillance of Vaccine Preventable Diseases, 2008-2009 2011, Centers for Disease Control and Prevention, Accessed 22 December 2011 at: http://www.cdc.gov/vaccines/pubs/surv-manual/index.html. 5th edition.